145 related articles for article (PubMed ID: 18418814)
1. Synthesis and in vitro evaluation of alpha-GalCer epimers.
Trappeniers M; Goormans S; Van Beneden K; Decruy T; Linclau B; Al-Shamkhani A; Elliott T; Ottensmeier C; Werner JM; Elewaut D; Van Calenbergh S
ChemMedChem; 2008 Jul; 3(7):1061-70. PubMed ID: 18418814
[TBL] [Abstract][Full Text] [Related]
2. An alpha-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes.
Ly D; Tohn R; Rubin B; Blumenfeld H; Besra GS; Veerapen N; Porcelli SA; Delovitch TL
Clin Exp Immunol; 2010 May; 160(2):185-98. PubMed ID: 20015094
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological activities of amino acids functionalized α-GalCer analogues.
Ma W; Bi J; Zhao C; Zhang Z; Liu T; Zhang G
Bioorg Med Chem; 2020 Jan; 28(1):115141. PubMed ID: 31786009
[TBL] [Abstract][Full Text] [Related]
4. Regulation by Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 of alpha-galactosylceramide-induced antimetastatic activity and Th1 and Th2 responses of NKT cells.
Okajo J; Kaneko Y; Murata Y; Tomizawa T; Okuzawa C; Saito Y; Kaneko Y; Ishikawa-Sekigami T; Okazawa H; Ohnishi H; Matozaki T; Nojima Y
J Immunol; 2007 May; 178(10):6164-72. PubMed ID: 17475843
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways.
Hayakawa Y; Takeda K; Yagita H; Van Kaer L; Saiki I; Okumura K
J Immunol; 2001 May; 166(10):6012-8. PubMed ID: 11342617
[TBL] [Abstract][Full Text] [Related]
6. Raising the roof: the preferential pharmacological stimulation of Th1 and th2 responses mediated by NKT cells.
East JE; Kennedy AJ; Webb TJ
Med Res Rev; 2014 Jan; 34(1):45-76. PubMed ID: 23239102
[TBL] [Abstract][Full Text] [Related]
7. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.
Hong S; Wilson MT; Serizawa I; Wu L; Singh N; Naidenko OV; Miura T; Haba T; Scherer DC; Wei J; Kronenberg M; Koezuka Y; Van Kaer L
Nat Med; 2001 Sep; 7(9):1052-6. PubMed ID: 11533710
[TBL] [Abstract][Full Text] [Related]
8. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids.
Chang YJ; Huang JR; Tsai YC; Hung JT; Wu D; Fujio M; Wong CH; Yu AL
Proc Natl Acad Sci U S A; 2007 Jun; 104(25):10299-304. PubMed ID: 17566107
[TBL] [Abstract][Full Text] [Related]
9. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
[TBL] [Abstract][Full Text] [Related]
10. Regulation of immune responses by CD1d-restricted natural killer T cells.
Van Kaer L
Immunol Res; 2004; 30(2):139-53. PubMed ID: 15477656
[TBL] [Abstract][Full Text] [Related]
11. 3-fluoro- and 3,3-difluoro-3,4-dideoxy-KRN7000 analogues as new potent immunostimulator agents: total synthesis and biological evaluation in human invariant natural killer T cells and mice.
Hunault J; Diswall M; Frison JC; Blot V; Rocher J; Marionneau-Lambot S; Oullier T; Douillard JY; Guillarme S; Saluzzo C; Dujardin G; Jacquemin D; Graton J; Le Questel JY; Evain M; Lebreton J; Dubreuil D; Le Pendu J; Pipelier M
J Med Chem; 2012 Feb; 55(3):1227-41. PubMed ID: 22243602
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological activity of hydroxylated analogues of KRN7000 (α-galactosylceramide).
Shiozaki M; Tashiro T; Koshino H; Shigeura T; Watarai H; Taniguchi M; Mori K
Carbohydr Res; 2013 Apr; 370():46-66. PubMed ID: 23454137
[TBL] [Abstract][Full Text] [Related]
13. 4,5-cis unsaturated α-GalCer analogues distinctly lead to CD1d-mediated Th1-biased NKT cell responses.
Cui Y; Li Z; Cheng Z; Xia C; Zhang Y
Chem Res Toxicol; 2015 Jun; 28(6):1209-15. PubMed ID: 25955524
[TBL] [Abstract][Full Text] [Related]
14. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype.
Singh N; Hong S; Scherer DC; Serizawa I; Burdin N; Kronenberg M; Koezuka Y; Van Kaer L
J Immunol; 1999 Sep; 163(5):2373-7. PubMed ID: 10452969
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of sphinganine analogues of KRN7000 and OCH.
Ndonye RM; Izmirian DP; Dunn MF; Yu KO; Porcelli SA; Khurana A; Kronenberg M; Richardson SK; Howell AR
J Org Chem; 2005 Dec; 70(25):10260-70. PubMed ID: 16323834
[TBL] [Abstract][Full Text] [Related]
16. Syntheses of biotinylated alpha-galactosylceramides and their effects on the immune system and CD1 molecules.
Sakai T; Naidenko OV; Iijima H; Kronenberg M; Koezuka Y
J Med Chem; 1999 May; 42(10):1836-41. PubMed ID: 10346936
[TBL] [Abstract][Full Text] [Related]
17. Modulation of NKT cells and Th1/Th2 imbalance after alpha-GalCer treatment in progressive load-trained rats.
Ru W; Peijie C
Int J Biol Sci; 2009 May; 5(4):338-43. PubMed ID: 19461936
[TBL] [Abstract][Full Text] [Related]
18. RCAI-17, 22, 24-26, 29, 31, 34-36, 38-40, and 88, the analogs of KRN7000 with a sulfonamide linkage: their synthesis and bioactivity for mouse natural killer T cells to produce Th2-biased cytokines.
Tashiro T; Hongo N; Nakagawa R; Seino K; Watarai H; Ishii Y; Taniguchi M; Mori K
Bioorg Med Chem; 2008 Oct; 16(19):8896-906. PubMed ID: 18790646
[TBL] [Abstract][Full Text] [Related]
19. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of truncated analogues of the iNKT cell agonist, α-galactosyl ceramide (KRN7000), and their biological evaluation.
Veerapen N; Reddington F; Salio M; Cerundolo V; Besra GS
Bioorg Med Chem; 2011 Jan; 19(1):221-8. PubMed ID: 21145749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
